Atlanta Capital Management Co. L L C Trims Position in Henry Schein, Inc. (HSIC)
Atlanta Capital Management Co. L L C lessened its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 15.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,250,205 shares of the company’s stock after selling 230,366 shares during the period. Henry Schein makes up about 1.3% of Atlanta Capital Management Co. L L C’s investment portfolio, making the stock its 28th largest position. Atlanta Capital Management Co. L L C owned about 1.58% of Henry Schein worth $228,813,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in HSIC. Waldron LP bought a new stake in Henry Schein in the first quarter worth $286,000. Victory Capital Management Inc. increased its position in Henry Schein by 16.0% in the first quarter. Victory Capital Management Inc. now owns 9,112 shares of the company’s stock worth $1,549,000 after purchasing an additional 1,256 shares during the last quarter. Van ECK Associates Corp increased its position in Henry Schein by 5.7% in the first quarter. Van ECK Associates Corp now owns 1,138 shares of the company’s stock worth $193,000 after purchasing an additional 61 shares during the last quarter. OppenheimerFunds Inc. increased its position in Henry Schein by 1.6% in the first quarter. OppenheimerFunds Inc. now owns 8,611 shares of the company’s stock worth $1,464,000 after purchasing an additional 135 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in Henry Schein by 116.0% in the first quarter. Wellington Management Group LLP now owns 13,386 shares of the company’s stock worth $2,275,000 after purchasing an additional 7,189 shares during the last quarter. Institutional investors own 44.56% of the company’s stock.
Shares of Henry Schein, Inc. (HSIC) traded down 1.14% during mid-day trading on Monday, hitting $80.07. 441,364 shares of the stock were exchanged. The company has a 50-day moving average price of $83.51 and a 200-day moving average price of $87.53. The stock has a market cap of $12.66 billion, a price-to-earnings ratio of 23.40 and a beta of 1.09. Henry Schein, Inc. has a 12 month low of $73.11 and a 12 month high of $93.50.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.86 by $0.02. The firm had revenue of $3.06 billion during the quarter, compared to the consensus estimate of $3.05 billion. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The company’s quarterly revenue was up 6.4% on a year-over-year basis. During the same period last year, the company earned $0.82 EPS. Equities analysts expect that Henry Schein, Inc. will post $3.64 earnings per share for the current year.
Henry Schein announced that its Board of Directors has initiated a share repurchase program on Monday, September 18th that allows the company to buyback $400.00 million in shares. This buyback authorization allows the company to purchase up to 6.3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.
In related news, SVP Paul Rose sold 2,126 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $172.51, for a total transaction of $366,756.26. Following the completion of the sale, the senior vice president now directly owns 17,841 shares of the company’s stock, valued at approximately $3,077,750.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.27% of the stock is currently owned by company insiders.
Several brokerages recently weighed in on HSIC. Zacks Investment Research cut shares of Henry Schein from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Northcoast Research upgraded shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $109.00 price target on the stock in a research report on Monday, August 7th. BidaskClub lowered shares of Henry Schein from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC reaffirmed a “hold” rating and set a $88.50 price objective on shares of Henry Schein in a research note on Thursday, September 28th. Finally, Credit Suisse Group reaffirmed a “hold” rating and set a $80.00 price objective on shares of Henry Schein in a research note on Thursday, July 13th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Henry Schein has a consensus rating of “Hold” and a consensus price target of $92.17.
Henry Schein Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Stock Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related stocks with our FREE daily email newsletter.